Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512736 | 0.85 | GRM5 (0.45) | GRM5PIM1CYP3A4ALDH1A1MAPT | |
| SCHEMBL512328 | 0.83 | GRM5 (0.48) | GRM5CYP3A4ALDH1A1MAPTMAPK1 | |
| SCHEMBL512205 | 0.81 | GRM5 (0.42) | GRM5CYP3A4ALDH1A1MAPTMAPK1 | |
| SCHEMBL513266 | 0.79 | GRM5 (0.43) | GRM5CYP3A4ALDH1A1MAPTMAPK1 | |
| SCHEMBL512878 | 0.75 | GRM5 (0.44) | GRM5CYP3A4ALDH1A1MAPTMAPK1 | |
| SCHEMBL513213 | 0.75 | GRM5 (0.42) | GRM5CYP3A4ALDH1A1MAPTMAPK1 | |
| SCHEMBL513168 | 0.75 | GRM5 (0.42) | GRM5CYP3A4ALDH1A1MAPTMAPK1 | |
| SCHEMBL512762 | 0.71 | GRM5 (0.45) | GRM5CYP3A4ALDH1A1MAPTMAPK1 | |
| SCHEMBL512866 | 0.71 | GRM5 (0.48) | GRM5CYP3A4ALDH1A1MAPTMAPK1 | |
| SCHEMBL512658 | 0.71 | GRM5 (0.48) | GRM5CYP3A4ALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | claimed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | GRM5 2/4885PIM1 4820/4885CYP3A4 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.